newsfilter
← Latest News
GlobeNewswire·

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025